COMP <GO>
CMT vs TMO // EV/EBITDA & P/E VALUATION
Core Molding Technologies Inc (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CMT 2
— TMO 10
▲ EV/EBITDA & P/E VALUATION LEADER: CMT
LAST: $22.52 (+1.49%) • MKT CAP: $199.3M
valuation
6.2x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CMT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CMT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 17.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 9.30% | -1.10 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.2x | 30.4x | -24.20 | CMT | /valuation <GO> |
| Free Cash Flow Yield | 0.96% | 2.40% | -1.44 | TMO | /fcf-yield <GO> |
| Operating Margin | 5.20% | 17.40% | -12.20 | TMO | /operating-margins <GO> |
| Net Profit Margin | 4.10% | 15.10% | -11.00 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -9.50% | 3.90% | -13.40 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.38 | 4.50 | -0.12 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 62.9 | -19.79 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 36.3x | -19.70 | CMT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $199.3M | $262.22B | -$262.02B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CMT REV | TMO REV | CMT GROSS % | TMO GROSS % | CMT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $273.8M | $44.56B | 17.4% | — | $1.9M | $6.29B |
| FY 2024 | $302.4M | $42.88B | 17.6% | — | $23.6M | $7.27B |
| FY 2023 | $357.7M | $42.86B | — | — | $34.8M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CMT // BETA —
TMO // BETA 0.94